1. Home
  2. MNPR vs CODI Comparison

MNPR vs CODI Comparison

Compare MNPR & CODI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$97.79

Market Cap

587.4M

Sector

Health Care

ML Signal

HOLD

Logo D/B/A Compass Diversified Holdings Shares of Beneficial Interest

CODI

D/B/A Compass Diversified Holdings Shares of Beneficial Interest

HOLD

Current Price

$10.61

Market Cap

480.8M

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNPR
CODI
Founded
2014
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Home Furnishings
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
587.4M
480.8M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
MNPR
CODI
Price
$97.79
$10.61
Analyst Decision
Strong Buy
Hold
Analyst Count
11
2
Target Price
$107.00
$9.25
AVG Volume (30 Days)
144.8K
998.4K
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
54.99
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$5.25
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$29.18
$4.58
52 Week High
$105.00
$12.64

Technical Indicators

Market Signals
Indicator
MNPR
CODI
Relative Strength Index (RSI) 83.34 49.86
Support Level $52.92 $10.37
Resistance Level $103.17 $11.11
Average True Range (ATR) 6.06 0.57
MACD 2.84 0.11
Stochastic Oscillator 93.86 42.70

Price Performance

Historical Comparison
MNPR
CODI

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

About CODI D/B/A Compass Diversified Holdings Shares of Beneficial Interest

Compass Diversified Holdings is a diversified business conglomerate based in the United States having two groups: branded consumer business and industrial business. Branded consumer businesses are characterized as those businesses that capitalize on a valuable brand name in their respective market sector. It includes 5.11, Ergobaby, Liberty Safe, and Velocity Outdoor. Industrial businesses are characterized as those businesses that focus on manufacturing and selling particular products and industrial services within a specific market sector. The company has operations in the United States, Canada, Europe, Asia Pacific, and other International areas.

Share on Social Networks: